Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011;38(4):427-30.

Thrombus formation during percutaneous closure of an atrial septal defect with an Amplatzer septal occluder

Hikmet Yorgun  1 , Ugur Canpolat, Ergun Baris Kaya, Kudret Aytemir, Ali Oto
Affiliations
Case Reports

Thrombus formation during percutaneous closure of an atrial septal defect with an Amplatzer septal occluder

Hikmet Yorgun et al. Tex Heart Inst J. 2011.

Erratum in

  • Tex Heart Inst J. 2011;38(5):612. Dosage error in article text

Abstract

Percutaneous closure of an ostium secundum-type atrial septal defect is typically a safe and effective therapeutic option in the presence of significant shunting or paradoxical embolism. Infrequently, however, periprocedural sequelae occur.Herein, we report the cases of 2 patients, each of whom underwent transcatheter closure of an atrial septal defect with the use of an Amplatzer Septal Occluder under transesophageal echocardiographic guidance. In both patients, acute thrombi formed periprocedurally, despite preprocedural anticoagulation. In patient 1, the infusion of unfractionated heparin for 24 hours prevented the recurrence of thrombus; in patient 2, the thrombus was isolated under the arm of the occluder, and unfractionated heparin was infused. Both patients were asymptomatic and without detectable thrombus after the procedure and at follow-up. These reports highlight a rare early sequela and the importance of transesophageal echocardiographic monitoring during the percutaneous closure of an atrial septal defect.

Keywords: Anticoagulants/therapeutic use; blood coagulation/drug effects; echocardiography, transesophageal; heart catheterization/adverse effects; heart septal defects, atrial/blood/therapy; heparin/therapeutic use; prosthesis implantation/adverse effects/instrumentation; septal occluder device; thrombosis/drug therapy/etiology/prevention & control/ultrasonography; treatment outcome.

PubMed Disclaimer

Figures

None
Fig. 1 Patient 1. Transesophageal echocardiography shows A) thrombus formation on the right atrial edge of the Amplatzer septal occluder, and B) no thrombus on the device after unfractionated heparin was infused.
None
Fig. 2 Patient 2. Transesophageal echocardiography shows A) thrombus formation at the tip of the delivery sheath during percutaneous atrial septal defect closure, and B) no thrombus around the occluder device postprocedurally.
See this image and copyright information in PMC

References

    1. Therien J, Webb G. Congenital heart diseases in adults. In: Braunwald E, Zipes DP, Libby P, editors. Heart disease: a textbook of cardiovascular medicine. 6th ed. Philadelphia: WB Saunders; 2001. p. 1592–621.
    1. Fiarresga A, De Sousa L, Martins JD, Ramos R, Parames F, Freitas I, et al. Percutaneous closure of atrial septal defects: a decade of experience at a reference center [in English, Portuguese]. Rev Port Cardiol 2010;29(5):767–80. - PubMed
    1. La Rosee K, Deutsch HJ, Schnabel P, Schneider CA, Burkhard-Meier C, Hopp HW. Thrombus formation after transcatheter closure of atrial septal defect. Am J Cardiol 1999;84 (3):356–9, A9. - PubMed
    1. Hanzel GS. Complications of patent foramen ovale and atrial septal defect closure devices. J Interv Cardiol 2006;19(2):160–2. - PubMed
    1. Nkomo VT, Theuma P, Maniu CV, Chandrasekaran K, Miller FA, Schaff HV, et al. Patent foramen ovale transcatheter closure device thrombosis. Mayo Clin Proc 2001;76(10): 1057–61. - PubMed

Publication types

MeSH terms

LinkOut - more resources